US invests $481M in startup that supplied NBA coronavirus tests

Maia Anderson –
Wednesday, October 14th, 2020
Print|Email.

Hint Health, based in San Diego, said it will increase its production of the point-of-care test from numerous thousand kits daily to 100,000 daily by March. The U.S. strategies to acquire 6 million tests and 30,000 laboratory instruments from the company..

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

The U.S. is investing $481 million in a startup diagnostics company to increase production of its point-of-care COVID-19 test, the exact same one used by the NBA this season.

The test was used effectively by the NBA in its “bubble” in Orlando, Fla., this season, CNBC reported..

More posts on supply chain:171 COVID-19 testing sites purchased shut for failing to meet US standardsAmazon kinds partnership to improve temperature-sensitive vaccine distributionLabs squeezed for personnel to fulfill COVID-19 testing demand.

The test was studied by the Mayo Clinic in Rochester, Minn., however research study outcomes have not been published. The FDA gave the test emergency situation usage permission on June 12 and permitted its usage anywhere under supervision of competent medical workers..

The molecular test produces lead to about 20 minutes and utilizes a nasal swab that takes a sample from the lower part of the nose, instead of the more typically utilized nasopharyngeal swabs that take samples from deep inside the nose. Test results are delivered through a mobile app..

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

Hint Health CEO Ayub Khattak told CNBC the company hopes to get the test licensed for at-home usage.